http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 11:11:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/UCB+Launches+Career-Advancing+Scholarship+Program+for+Adults+Living+with+Hidradenitis+Suppurativa+and+Immediate+Family+Members/26581182.html <div class="xn-content"> <ul type="disc"><li>Applications open <chron>June 1</chron> for UCB's Hidradenitis Suppurativa Scholarship™ Program</li><li>Informed by patient insights, the initiative builds on UCB's network of scholarship programs in myasthenia gravis and epilepsy</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the launch of the inaugural UCB Hidradenitis Suppurativa Scholarship™ Program, designed to support adults age 18 and older living with hidradenitis suppurativa (HS), and their immediate family members, in pursuing education and career development.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/UCB+Launches+Career-Advancing+Scholarship+Program+for+Adults+Living+with+Hidradenitis+Suppurativa+and+Immediate+Family+Members/26581182.html Mon, 01 Jun 2026 11:11:00 -0400 O.19039711 UCB UCBJY http://www.streetinsider.com/Press+Releases/UCB+Launches+Career-Advancing+Scholarship+Program+for+Adults+Living+with+Hidradenitis+Suppurativa+and+Immediate+Family+Members/26581182.html <div class="xn-content"> <ul type="disc"><li>Applications open <chron>June 1</chron> for UCB's Hidradenitis Suppurativa Scholarship™ Program</li><li>Informed by patient insights, the initiative builds on UCB's network of scholarship programs in myasthenia gravis and epilepsy</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the launch of the inaugural UCB Hidradenitis Suppurativa Scholarship™ Program, designed to support adults age 18 and older living with hidradenitis suppurativa (HS), and their immediate family members, in pursuing education and career development.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/UCB+Launches+Career-Advancing+Scholarship+Program+for+Adults+Living+with+Hidradenitis+Suppurativa+and+Immediate+Family+Members/26581182.html Mon, 01 Jun 2026 11:11:00 -0400 O.19039711 UCB UCBJY http://www.streetinsider.com/Press+Releases/UCB+Launches+Career-Advancing+Scholarship+Program+for+Adults+Living+with+Hidradenitis+Suppurativa+and+Immediate+Family+Members/26581182.html <div class="xn-content"> <ul type="disc"><li>Applications open <chron>June 1</chron> for UCB's Hidradenitis Suppurativa Scholarship™ Program</li><li>Informed by patient insights, the initiative builds on UCB's network of scholarship programs in myasthenia gravis and epilepsy</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the launch of the inaugural UCB Hidradenitis Suppurativa Scholarship™ Program, designed to support adults age 18 and older living with hidradenitis suppurativa (HS), and their immediate family members, in pursuing education and career development.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/UCB+Launches+Career-Advancing+Scholarship+Program+for+Adults+Living+with+Hidradenitis+Suppurativa+and+Immediate+Family+Members/26581182.html Mon, 01 Jun 2026 11:11:00 -0400 O.19039711 UCB UCBJY http://www.streetinsider.com/PRNewswire/UCB+Launches+Career-Advancing+Scholarship+Program+for+Adults+Living+with+Hidradenitis+Suppurativa+and+Immediate+Family+Members/26581182.html <div class="xn-content"> <ul type="disc"><li>Applications open <chron>June 1</chron> for UCB's Hidradenitis Suppurativa Scholarship™ Program</li><li>Informed by patient insights, the initiative builds on UCB's network of scholarship programs in myasthenia gravis and epilepsy</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the launch of the inaugural UCB Hidradenitis Suppurativa Scholarship™ Program, designed to support adults age 18 and older living with hidradenitis suppurativa (HS), and their immediate family members, in pursuing education and career development.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/UCB+Launches+Career-Advancing+Scholarship+Program+for+Adults+Living+with+Hidradenitis+Suppurativa+and+Immediate+Family+Members/26581182.html Mon, 01 Jun 2026 11:11:00 -0400 O.19039711 UCB UCBJY http://www.streetinsider.com/PRNewswire/UCB+Launches+Career-Advancing+Scholarship+Program+for+Adults+Living+with+Hidradenitis+Suppurativa+and+Immediate+Family+Members/26581182.html <div class="xn-content"> <ul type="disc"><li>Applications open <chron>June 1</chron> for UCB's Hidradenitis Suppurativa Scholarship™ Program</li><li>Informed by patient insights, the initiative builds on UCB's network of scholarship programs in myasthenia gravis and epilepsy</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the launch of the inaugural UCB Hidradenitis Suppurativa Scholarship™ Program, designed to support adults age 18 and older living with hidradenitis suppurativa (HS), and their immediate family members, in pursuing education and career development.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/UCB+Launches+Career-Advancing+Scholarship+Program+for+Adults+Living+with+Hidradenitis+Suppurativa+and+Immediate+Family+Members/26581182.html Mon, 01 Jun 2026 11:11:00 -0400 O.19039711 UCB UCBJY http://www.streetinsider.com/PRNewswire/UCB+Launches+Career-Advancing+Scholarship+Program+for+Adults+Living+with+Hidradenitis+Suppurativa+and+Immediate+Family+Members/26581182.html <div class="xn-content"> <ul type="disc"><li>Applications open <chron>June 1</chron> for UCB's Hidradenitis Suppurativa Scholarship™ Program</li><li>Informed by patient insights, the initiative builds on UCB's network of scholarship programs in myasthenia gravis and epilepsy</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the launch of the inaugural UCB Hidradenitis Suppurativa Scholarship™ Program, designed to support adults age 18 and older living with hidradenitis suppurativa (HS), and their immediate family members, in pursuing education and career development.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/UCB+Launches+Career-Advancing+Scholarship+Program+for+Adults+Living+with+Hidradenitis+Suppurativa+and+Immediate+Family+Members/26581182.html Mon, 01 Jun 2026 11:11:00 -0400 O.19039711 UCB UCBJY http://www.streetinsider.com/SEC+Filings/Form++425++++++++UNITED+COMMUNITY+BANKS+++++++++++++++++Filed+by%3A+UNITED+COMMUNITY+BANKS+INC/26573794.html si-local-file:///var/storage/secattach/20260529/26573794.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++UNITED+COMMUNITY+BANKS+++++++++++++++++Filed+by%3A+UNITED+COMMUNITY+BANKS+INC/26573794.html Fri, 29 May 2026 14:24:00 -0400 O.00178515 UCB http://www.streetinsider.com/SEC+Filings/Form++425++++++++UNITED+COMMUNITY+BANKS+++++++++++++++++Filed+by%3A+UNITED+COMMUNITY+BANKS+INC/26573794.html si-local-file:///var/storage/secattach/20260529/26573794.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++UNITED+COMMUNITY+BANKS+++++++++++++++++Filed+by%3A+UNITED+COMMUNITY+BANKS+INC/26573794.html Fri, 29 May 2026 14:24:00 -0400 O.00178515 UCB http://www.streetinsider.com/SEC+Filings/Form++S-4++++++++UNITED+COMMUNITY+BANKS+++++++++++++++/26567402.html si-local-file:///var/storage/secattach/20260528/26567402.html http://www.streetinsider.com/SEC+Filings/Form++S-4++++++++UNITED+COMMUNITY+BANKS+++++++++++++++/26567402.html Thu, 28 May 2026 16:12:00 -0400 O.00178515 UCB http://www.streetinsider.com/SEC+Filings/Form++S-4++++++++UNITED+COMMUNITY+BANKS+++++++++++++++/26567402.html si-local-file:///var/storage/secattach/20260528/26567402.html http://www.streetinsider.com/SEC+Filings/Form++S-4++++++++UNITED+COMMUNITY+BANKS+++++++++++++++/26567402.html Thu, 28 May 2026 16:12:00 -0400 O.00178515 UCB http://www.streetinsider.com/SEC+Filings/Form++425++++++++UNITED+COMMUNITY+BANKS+++++++++++++++++Filed+by%3A+UNITED+COMMUNITY+BANKS+INC/26538798.html si-local-file:///var/storage/secattach/20260522/26538798.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++UNITED+COMMUNITY+BANKS+++++++++++++++++Filed+by%3A+UNITED+COMMUNITY+BANKS+INC/26538798.html Fri, 22 May 2026 08:26:00 -0400 O.00178515 UCB http://www.streetinsider.com/SEC+Filings/Form++425++++++++UNITED+COMMUNITY+BANKS+++++++++++++++++Filed+by%3A+UNITED+COMMUNITY+BANKS+INC/26538798.html si-local-file:///var/storage/secattach/20260522/26538798.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++UNITED+COMMUNITY+BANKS+++++++++++++++++Filed+by%3A+UNITED+COMMUNITY+BANKS+INC/26538798.html Fri, 22 May 2026 08:26:00 -0400 O.00178515 UCB http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html <div class="xn-content"> <ul type="disc"><li><b>BIMZELX is the first approved biologic therapy to demonstrate superior, head-to-head ACR50 joint outcomes in psoriatic arthritis: </b>49.1% of those receiving BIMZELX vs 38.4% receiving risankizumab achieved the stringent ACR50 primary endpoint at Week 16^{1<br /><br />}</li><li><b>Improvements in secondary endpoints: </b>Numerically greater responses without statistical significance were observed for BIMZELX vs risankizumab across all secondary endpoints, with no new safety signals observed^{1<br /><br />}</li><li><b>Greater improvements in joint relief at Week 4: </b>The secondary endpoint of ACR50 at Week 4 was 19.9% for those receiving BIMZELX vs 7.2% for those receiving risankizumab¹<b>^{*<br /><br />}</b></li><li><b>Complete skin clearance: </b>53.4% of those http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html Tue, 19 May 2026 15:14:00 -0400 A.18955402 A.27354763 A.39102015 A.60012014 O.02267979 O.19039711 O.39153139 O.48492100 O.51030022 UCB UCBJY http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html <div class="xn-content"> <ul type="disc"><li><b>BIMZELX is the first approved biologic therapy to demonstrate superior, head-to-head ACR50 joint outcomes in psoriatic arthritis: </b>49.1% of those receiving BIMZELX vs 38.4% receiving risankizumab achieved the stringent ACR50 primary endpoint at Week 16^{1<br /><br />}</li><li><b>Improvements in secondary endpoints: </b>Numerically greater responses without statistical significance were observed for BIMZELX vs risankizumab across all secondary endpoints, with no new safety signals observed^{1<br /><br />}</li><li><b>Greater improvements in joint relief at Week 4: </b>The secondary endpoint of ACR50 at Week 4 was 19.9% for those receiving BIMZELX vs 7.2% for those receiving risankizumab¹<b>^{*<br /><br />}</b></li><li><b>Complete skin clearance: </b>53.4% of those http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html Tue, 19 May 2026 15:14:00 -0400 A.18955402 A.27354763 A.39102015 A.60012014 O.02267979 O.19039711 O.39153139 O.48492100 O.51030022 UCB UCBJY http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html <div class="xn-content"> <ul type="disc"><li><b>BIMZELX is the first approved biologic therapy to demonstrate superior, head-to-head ACR50 joint outcomes in psoriatic arthritis: </b>49.1% of those receiving BIMZELX vs 38.4% receiving risankizumab achieved the stringent ACR50 primary endpoint at Week 16^{1<br /><br />}</li><li><b>Improvements in secondary endpoints: </b>Numerically greater responses without statistical significance were observed for BIMZELX vs risankizumab across all secondary endpoints, with no new safety signals observed^{1<br /><br />}</li><li><b>Greater improvements in joint relief at Week 4: </b>The secondary endpoint of ACR50 at Week 4 was 19.9% for those receiving BIMZELX vs 7.2% for those receiving risankizumab¹<b>^{*<br /><br />}</b></li><li><b>Complete skin clearance: </b>53.4% of those http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html Tue, 19 May 2026 15:14:00 -0400 A.18955402 A.27354763 A.39102015 A.60012014 O.02267979 O.19039711 O.39153139 O.48492100 O.51030022 UCB UCBJY http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html <div class="xn-content"> <ul type="disc"><li><b>BIMZELX is the first approved biologic therapy to demonstrate superior, head-to-head ACR50 joint outcomes in psoriatic arthritis: </b>49.1% of those receiving BIMZELX vs 38.4% receiving risankizumab achieved the stringent ACR50 primary endpoint at Week 16^{1<br /><br />}</li><li><b>Improvements in secondary endpoints: </b>Numerically greater responses without statistical significance were observed for BIMZELX vs risankizumab across all secondary endpoints, with no new safety signals observed^{1<br /><br />}</li><li><b>Greater improvements in joint relief at Week 4: </b>The secondary endpoint of ACR50 at Week 4 was 19.9% for those receiving BIMZELX vs 7.2% for those receiving risankizumab¹<b>^{*<br /><br />}</b></li><li><b>Complete skin clearance: </b>53.4% of those http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html Tue, 19 May 2026 15:14:00 -0400 A.18955402 A.27354763 A.39102015 A.60012014 O.02267979 O.19039711 O.39153139 O.48492100 O.51030022 UCB UCBJY http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html <div class="xn-content"> <ul type="disc"><li><b>BIMZELX is the first approved biologic therapy to demonstrate superior, head-to-head ACR50 joint outcomes in psoriatic arthritis: </b>49.1% of those receiving BIMZELX vs 38.4% receiving risankizumab achieved the stringent ACR50 primary endpoint at Week 16^{1<br /><br />}</li><li><b>Improvements in secondary endpoints: </b>Numerically greater responses without statistical significance were observed for BIMZELX vs risankizumab across all secondary endpoints, with no new safety signals observed^{1<br /><br />}</li><li><b>Greater improvements in joint relief at Week 4: </b>The secondary endpoint of ACR50 at Week 4 was 19.9% for those receiving BIMZELX vs 7.2% for those receiving risankizumab¹<b>^{*<br /><br />}</b></li><li><b>Complete skin clearance: </b>53.4% of those http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html Tue, 19 May 2026 15:14:00 -0400 A.18955402 A.27354763 A.39102015 A.60012014 O.02267979 O.19039711 O.39153139 O.48492100 O.51030022 UCB UCBJY http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html <div class="xn-content"> <ul type="disc"><li><b>BIMZELX is the first approved biologic therapy to demonstrate superior, head-to-head ACR50 joint outcomes in psoriatic arthritis: </b>49.1% of those receiving BIMZELX vs 38.4% receiving risankizumab achieved the stringent ACR50 primary endpoint at Week 16^{1<br /><br />}</li><li><b>Improvements in secondary endpoints: </b>Numerically greater responses without statistical significance were observed for BIMZELX vs risankizumab across all secondary endpoints, with no new safety signals observed^{1<br /><br />}</li><li><b>Greater improvements in joint relief at Week 4: </b>The secondary endpoint of ACR50 at Week 4 was 19.9% for those receiving BIMZELX vs 7.2% for those receiving risankizumab¹<b>^{*<br /><br />}</b></li><li><b>Complete skin clearance: </b>53.4% of those http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html Tue, 19 May 2026 15:14:00 -0400 A.18955402 A.27354763 A.39102015 A.60012014 O.02267979 O.19039711 O.39153139 O.48492100 O.51030022 UCB UCBJY http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html <div class="xn-content"> <ul type="disc"><li><b>BIMZELX is the first approved biologic therapy to demonstrate superior, head-to-head ACR50 joint outcomes in psoriatic arthritis: </b>49.1% of those receiving BIMZELX vs 38.4% receiving risankizumab achieved the stringent ACR50 primary endpoint at Week 16^{1<br /><br />}</li><li><b>Improvements in secondary endpoints: </b>Numerically greater responses without statistical significance were observed for BIMZELX vs risankizumab across all secondary endpoints, with no new safety signals observed^{1<br /><br />}</li><li><b>Greater improvements in joint relief at Week 4: </b>The secondary endpoint of ACR50 at Week 4 was 19.9% for those receiving BIMZELX vs 7.2% for those receiving risankizumab¹<b>^{*<br /><br />}</b></li><li><b>Complete skin clearance: </b>53.4% of those http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html Tue, 19 May 2026 15:14:00 -0400 A.18955402 A.27354763 A.39102015 A.60012014 O.02267979 O.19039711 O.39153139 O.48492100 O.51030022 UCB UCBJY http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html <div class="xn-content"> <ul type="disc"><li><b>BIMZELX is the first approved biologic therapy to demonstrate superior, head-to-head ACR50 joint outcomes in psoriatic arthritis: </b>49.1% of those receiving BIMZELX vs 38.4% receiving risankizumab achieved the stringent ACR50 primary endpoint at Week 16^{1<br /><br />}</li><li><b>Improvements in secondary endpoints: </b>Numerically greater responses without statistical significance were observed for BIMZELX vs risankizumab across all secondary endpoints, with no new safety signals observed^{1<br /><br />}</li><li><b>Greater improvements in joint relief at Week 4: </b>The secondary endpoint of ACR50 at Week 4 was 19.9% for those receiving BIMZELX vs 7.2% for those receiving risankizumab¹<b>^{*<br /><br />}</b></li><li><b>Complete skin clearance: </b>53.4% of those http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html Tue, 19 May 2026 15:14:00 -0400 A.18955402 A.27354763 A.39102015 A.60012014 O.02267979 O.19039711 O.39153139 O.48492100 O.51030022 UCB UCBJY http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html <div class="xn-content"> <ul type="disc"><li><b>BIMZELX is the first approved biologic therapy to demonstrate superior, head-to-head ACR50 joint outcomes in psoriatic arthritis: </b>49.1% of those receiving BIMZELX vs 38.4% receiving risankizumab achieved the stringent ACR50 primary endpoint at Week 16^{1<br /><br />}</li><li><b>Improvements in secondary endpoints: </b>Numerically greater responses without statistical significance were observed for BIMZELX vs risankizumab across all secondary endpoints, with no new safety signals observed^{1<br /><br />}</li><li><b>Greater improvements in joint relief at Week 4: </b>The secondary endpoint of ACR50 at Week 4 was 19.9% for those receiving BIMZELX vs 7.2% for those receiving risankizumab¹<b>^{*<br /><br />}</b></li><li><b>Complete skin clearance: </b>53.4% of those http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html Tue, 19 May 2026 15:14:00 -0400 A.18955402 A.27354763 A.39102015 A.60012014 O.02267979 O.19039711 O.39153139 O.48492100 O.51030022 UCB UCBJY http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html <div class="xn-content"> <ul type="disc"><li><b>BIMZELX is the first approved biologic therapy to demonstrate superior, head-to-head ACR50 joint outcomes in psoriatic arthritis: </b>49.1% of those receiving BIMZELX vs 38.4% receiving risankizumab achieved the stringent ACR50 primary endpoint at Week 16^{1<br /><br />}</li><li><b>Improvements in secondary endpoints: </b>Numerically greater responses without statistical significance were observed for BIMZELX vs risankizumab across all secondary endpoints, with no new safety signals observed^{1<br /><br />}</li><li><b>Greater improvements in joint relief at Week 4: </b>The secondary endpoint of ACR50 at Week 4 was 19.9% for those receiving BIMZELX vs 7.2% for those receiving risankizumab¹<b>^{*<br /><br />}</b></li><li><b>Complete skin clearance: </b>53.4% of those http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html Tue, 19 May 2026 15:14:00 -0400 A.18955402 A.27354763 A.39102015 A.60012014 O.02267979 O.19039711 O.39153139 O.48492100 O.51030022 UCB UCBJY http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html <div class="xn-content"> <ul type="disc"><li><b>BIMZELX is the first approved biologic therapy to demonstrate superior, head-to-head ACR50 joint outcomes in psoriatic arthritis: </b>49.1% of those receiving BIMZELX vs 38.4% receiving risankizumab achieved the stringent ACR50 primary endpoint at Week 16^{1<br /><br />}</li><li><b>Improvements in secondary endpoints: </b>Numerically greater responses without statistical significance were observed for BIMZELX vs risankizumab across all secondary endpoints, with no new safety signals observed^{1<br /><br />}</li><li><b>Greater improvements in joint relief at Week 4: </b>The secondary endpoint of ACR50 at Week 4 was 19.9% for those receiving BIMZELX vs 7.2% for those receiving risankizumab¹<b>^{*<br /><br />}</b></li><li><b>Complete skin clearance: </b>53.4% of those http://www.streetinsider.com/Press+Releases/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html Tue, 19 May 2026 15:14:00 -0400 A.18955402 A.27354763 A.39102015 A.60012014 O.02267979 O.19039711 O.39153139 O.48492100 O.51030022 UCB UCBJY http://www.streetinsider.com/PRNewswire/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html <div class="xn-content"> <ul type="disc"><li><b>BIMZELX is the first approved biologic therapy to demonstrate superior, head-to-head ACR50 joint outcomes in psoriatic arthritis: </b>49.1% of those receiving BIMZELX vs 38.4% receiving risankizumab achieved the stringent ACR50 primary endpoint at Week 16^{1<br /><br />}</li><li><b>Improvements in secondary endpoints: </b>Numerically greater responses without statistical significance were observed for BIMZELX vs risankizumab across all secondary endpoints, with no new safety signals observed^{1<br /><br />}</li><li><b>Greater improvements in joint relief at Week 4: </b>The secondary endpoint of ACR50 at Week 4 was 19.9% for those receiving BIMZELX vs 7.2% for those receiving risankizumab¹<b>^{*<br /><br />}</b></li><li><b>Complete skin clearance: </b>53.4% of those http://www.streetinsider.com/PRNewswire/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html Tue, 19 May 2026 15:14:00 -0400 A.18955402 A.27354763 A.39102015 A.60012014 O.02267979 O.19039711 O.39153139 O.48492100 O.51030022 UCB UCBJY http://www.streetinsider.com/PRNewswire/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html <div class="xn-content"> <ul type="disc"><li><b>BIMZELX is the first approved biologic therapy to demonstrate superior, head-to-head ACR50 joint outcomes in psoriatic arthritis: </b>49.1% of those receiving BIMZELX vs 38.4% receiving risankizumab achieved the stringent ACR50 primary endpoint at Week 16^{1<br /><br />}</li><li><b>Improvements in secondary endpoints: </b>Numerically greater responses without statistical significance were observed for BIMZELX vs risankizumab across all secondary endpoints, with no new safety signals observed^{1<br /><br />}</li><li><b>Greater improvements in joint relief at Week 4: </b>The secondary endpoint of ACR50 at Week 4 was 19.9% for those receiving BIMZELX vs 7.2% for those receiving risankizumab¹<b>^{*<br /><br />}</b></li><li><b>Complete skin clearance: </b>53.4% of those http://www.streetinsider.com/PRNewswire/BIMZELX%C2%AE+%28bimekizumab-bkzx%29+demonstrates+superior+efficacy+over+SKYRIZI%C2%AE+%28risankizumab-rzaa%29+in+psoriatic+arthritis%3A+BE+BOLD+Week+16+data/26520631.html Tue, 19 May 2026 15:14:00 -0400 A.18955402 A.27354763 A.39102015 A.60012014 O.02267979 O.19039711 O.39153139 O.48492100 O.51030022 UCB UCBJY